Innovation and Northwestern University Phone 847-467-2097 Northwestern |INVO New Ventures Office 1800 Sherman Ave, Suite 504 invo.northwestern.edu Innovation and New Ventures Evanston, IL 60201
Exhibit 10.26
Innovation and | Northwestern University | Phone 000-000-0000 | Northwestern |INVO |
New Ventures Office | 0000 Xxxxxxx Xxx, Xxxxx 000 | xxxx.xxxxxxxxxxxx.xxx | Innovation and New Ventures |
Xxxxxxxx, XX 00000 | |||
June 11, 2018
Xxxxx X Xxxxxxxxx, Ph.D.
Chief Executive Officer
0000 Xxxxx Xxx.
Xxxxxx, XX 00000
Re: Amendment One to the License Agreement titled NU Exicure Liposomal Particles License Agreement dated May 27, 2014 ('Agreement") between Exicure, lnc("Exicure") and Northwestern University ("Northwestern').
Dear Xxxxx:
The following letter memorializes the understanding reached between Northwestern and Exicure regarding the First Amendment to the Agreement ("Amendment One NU- Exicure Liposomal). Unless otherwise defined In this Agreement, capitalized terms shall have the meaning assigned to them in the Agreement.
Subject to the terms and conditions of the Agreement and Exicure's compliance therewith, the parties hereby agree as follows:
1. | Exhibit A of the License Agreement is amended and incorporated herein by reference. |
2. | All other terms and conditions of the Agreement shall remain in full force and effect as amended hereby. |
By signing below, the parties hereby execute this valid and binding agreement effective as of the date listed above.
NORTHWESTERN UNIVERSITY | ||
/s/ Xxxxxx Xxxxxxx, Ph.D. | /s/ Xxxxx X. Xxxxxxxxx, Ph.D. | |
Xxxxxx Xxxxxxx, Ph.D. | Xxxxx X. Xxxxxxxxx, Ph.D. | |
Associate Vice President for Research | Chief Executive Officer | |
and Executive Director | ||
INVO, Northwestern University | ||
THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.
Innovation and | Northwestern University | Phone 000-000-0000 | Northwestern |INVO |
New Ventures Office | 0000 Xxxxxxx Xxx, Xxxxx 000 | xxxx.xxxxxxxxxxxx.xxx | Innovation and New Ventures |
Xxxxxxxx, XX 00000 | |||
Exhibit A:
NU# | Serial Application Number | Application Title | Application Type | Status | Country Code | File Date |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
***** | ***** | ***** | ***** | ***** | ***** | ***** |
THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.
